Merck gets cancer drug bar as Halozyme wins cross-border European injunction
A Dutch court barred Merck from manufacturing and marketing its under-the-skin version of Keytruda in eight European countries, ruling it infringes Halozyme's drug-delivery patent. The decision follows EU top court guidance on cross-border injunctions involving foreign patent rights.
How this was made
The 30-second read
Why it matters
The ruling creates immediate legal and commercial risk for Merck while strengthening Halozyme's IP position, affecting European oncology market dynamics.
Market read
Regulatory/legal news with direct impact on two listed pharma companies; potential short‑term price moves.
What to watch
Potential for settlement or licensing deal between Merck and Halozyme could mitigate long‑term impact.
Background
The article reports a Dutch court decision upholding Halozyme's patent, barring Merck from selling an under‑skin version of Keytruda in eight EU countries.
Ticker impact
Dutch court barred Merck's under‑skin Keytruda in eight EU countries due to Halozyme patent infringement.
likely pressure as investors price in restricted EU sales of Keytruda.
The injunction directly limits sales of a blockbuster drug in major European markets, creating immediate downside risk.
Market effects
May prompt re‑evaluation of oncology pipelines and patent risk across pharma sector.
European markets could see short‑term pressure on Merck shares; broader EU biotech sentiment may improve.
Highlights importance of IP enforcement in cross‑border drug commercialization.
Counterpoint
Investors might view the injunction as limited in scope, expecting Merck to pivot to other formulations or markets.
Key entities
- CompanyMerck Sharp & Dohme
US pharmaceutical giant barred from EU sales of Keytruda formulation.
- CompanyHalozyme Therapeutics
Patent holder whose drug‑delivery technology was upheld by the court.
